Slide 1: Elekta Capital Markets Day
Elekta Capital Markets Day 12 June 2013, Stockholm
Slide 2: Welcome to Elekta
Welcome to Elekta Capital Markets Day 2013 Tomas Puusepp President and CEO
Slide 3: Important information
Important information This presentation includes forward-looking statements including, but not limited to, statements relating to operational and financial performance, market conditions, and other similar matters. These forward-looking statements are based on current expectations about future event
Slide 4: Elekta is stronger than ever
Elekta is stronger than ever • Superior technology – Versa HDTM • No 1 in emerging markets – ~35% of Elekta’s order intake – >50% share of growth • No 1 in Europe and Asia Pacific • Growing faster than competition both with orders and revenues • EBIT- margin has expanded from 12% in 2004/05 to 20%
Slide 5: Strong growth with increased profitability
Strong growth with increased profitability SEK M Net Sales SEK M EBIT 2 000 10 000 CAGR CAGR 8 000 1 500 16% 24% Aftermarket and 6 000 Software sales 1 000 4 000 Hardware 500 2 000 0 0
Slide 6: Elekta has strengthened its position in radiation therapy
Elekta has strengthened its position in radiation therapy Trend Varian 49% Elekta 40% Accuray 8% Siemens 3% Others *- Note: Order intake. Sources – company reports * Accurate data missing
Slide 7: Elekta's aspiration
Elekta’s aspiration Aspiration 2 million • Increase usage of patients radiation therapy • Pioneer new technologies • Affordability, availability • Growing number of cancer patients Today: close to every year 1 million patients
Slide 8: Strategic agenda 2015/16 - focused on growth
Strategic agenda 2015/16 - focused on growth Ambition to grow net sales by 40%* from 2012/13 to 2015/16 1. Higher share of cancer care 2. Emerging markets – Availability – Training and education 3. Technology leadership – Image guided radiation therapy – MR Linac – Stereotactic radiation therapy and
Slide 9: From palliative to curative
From “palliative” to “curative” 1. Radiotherapy is a major contributor to improved cancer care • Technology advancements – Imaging – Precision – Motion management – Safety • Cost effective compared with chemotherapy and surgery
Slide 10: >50% of cancer patients receive radiation therapy in established markets
>50% of cancer patients receive radiation therapy in established markets Share of cancer patients receiving radiation therapy today • Increased efficiency USA 63% • Upgrades of installed base Europe 30-50% • Addition of new capacity Canada 32% • New bodysites Japan 25-30%
Slide 11: Elekta has strong performance in emerging markets
Elekta has strong performance 2. in emerging markets Elekta emerging markets Net sales, SEK bn Elekta emerging markets Market share CAGR 26% 3,3 ~50%* 2,6 >60%* 2,2 1,9 1,3 ~50%* ~50%* 08/09 09/10 10/11 11/12 12/13 * Elekta’s calculated market share
Slide 12: Emerging markets: Leadership and good growth
Emerging markets Leadership and good growth • Focus on training and education • Clinical solutions addressing specific needs in emerging markets • Increase own presence 2015/16E 2012/13 2004/05 40% 20% 31% 60% 69% 80% Emerging markets Established markets
Slide 13: Emerging markets: Need for new capacity
Emerging markets Need for new capacity Health care spend per capita and installed linacs per million inhabitants USD and units installed 12 USA 11 Linacs per million people 10 9 8 Western Europe 7 Japan 6 5 Canada 4 Southern Europe 3 Russia 2 Brazil 1 China South Africa India Turkey 0 0 500 1 000 1
Slide 14: Leading product portfolio
Leading product portfolio 3. Software Versa HD™ Solutions Brachy Leksell therapy Gamma Knife® Perfexion
Slide 15: Elekta is the pioneer of modern radiation therapy
Elekta is the pioneer of modern radiation therapy MR Linac MOSAIQ® OIS SRS Stereotactic Radiosurgery IGRT Digital linear Image guided accelerators radiation therapy Integrated solutions Versa HDTM Technological shift Brachytherapy SRT in collimation and high dose Stereotactic Radiotherapy
Slide 16: Versa HD
Versa HD™ the most advanced digital linear accelerator available 1. Enables higher dose to the tumor - more than three times faster than before 2. Minimizes dose to healthy tissue. MLC leaf speeds more than twice as fast as other systems 3. New generation of patient- specific treatments
Slide 17: Versa HD - exceeding expectations
Versa HD™ – exceeding expectations
Slide 18: Versa HD - strong demand and good uptake
Versa HD™ – strong demand and good uptake • CE Marked • 510(k) Cleared
Slide 19: Good demand for Leksell Gamma Knife
Good demand for Leksell Gamma Knife® • Patient volume growth year by year Metastatic tumors – Neurosurgery clinics CAGR 17 150 – Oncology clinics 11% – Metastatic tumors 9 055 • Unmatched precision in brain • Product development 2004 2010 focused on imaging
Slide 20: Brachytherapy - continuous innovation
Brachytherapy – continuous innovation • Expansion with current indications and add new – Rectal cancer – Skin cancer • Redesigned Flexitron afterloading platform launched in Q4 • Continued focus on installed base and recurrent revenue growth • Strong close of the fiscal year
Slide 21: MOSAIQ enables full product integration
Elekta Software MOSAIQ® enables full product integration Elekta treatment Versa HDTM planning portfolio Leksell Gamma Knife® MOSAIQ® Elekta Compact™ Brachytherapy Elekta Agility™ solutions
Slide 22: Elekta treatment planning system
Roadmap to market leadership Elekta treatment planning system MOSAIQ® RTP • Evaluate 510k Monaco Cleared Dec 2012, Elekta 5.0/5.1 CE Mark Feb 2013 • Locate Planning • Delineate Monaco Workspace • Simulate/Calculate Focal 4D FocalPro Oncentra 4.3 FocalSim ERGO++ XiO Oncentra ABAS
Slide 23: MR Linac
MR Linac Kevin Brown Global Vice President Scientific Research
Slide 24: Pioneering the next major breakthrough
Pioneering the next major breakthrough… State of the art MR imaging state of the art radiation therapy • Building on a decade of research from UMC, Utrecht, NL – In collaboration with Elekta and Philips • Research demonstrated unparalleled soft tissue visualization during irradiation • Research coll
Slide 25: Research into MRI-guided radiation therapy
Research into MRI-guided radiation therapy Experimental system at Utrecht, The Netherlands • MRI magnet full on at 1.5T and able to image • Linac able to radiate • MLC able to move leaves • Gantry able to rotate All at the same time!
Slide 26: Next steps...
Next steps... Developing a Global Research Consortium The MR Linac Consortium aims to: • Demonstrate improved patient outcomes for existing radiation therapy indications • Extend radiation therapy with new treatment techniques and be able to treat more indications Each consortium member will have a
Slide 27: Elekta and Philips research consortium press release
PHILIPS (*) ELEKTA Press information RI-Guided Radiation Therapy Adds eeuwenhoek Hospital eration radiotherapy innovation October 25, 2012 search Consortium on M Institute-Antoni van u Elekta and Philips Re ted to developing next-gen ha Netherlands Cancer ++ dladica 7 “YSE: thera the socnnd Magneti
Slide 28: Increased investments to the future of cancer care
Increased investments to the future of cancer care • Leadership in cancer care with linear accelerators • Drive SRS market with Groundbreaking R&D costs Leksell Gamma Knife® MR Linac approx. 10% of • Software – capture program net revenues full potential • Brachytherapy – develop new body sites
Slide 29: Elekta's strategy for sustainable profitable growth
Elekta’s strategy for sustainable profitable growth • Ambition to grow net sales by 40%* from 2012/13 to 2015/16 – Higher share of cancer care market – Emerging markets – Technology leadership • Continued EBITA growth – Expansion in Emerging Markets – Investments in R&D ~10% of net sales** – Continu
Slide 30: Financials
Financials Håkan Bergström CFO
Slide 31: Elekta's strategy for sustainable profitable growth
Elekta’s strategy for sustainable profitable growth • Ambition to grow net sales by 40%* from 2012/13 to 2015/16 – Higher share of cancer care market – Emerging markets – Technology leadership • Continued EBITA growth – Expansion in Emerging Markets – Investments in R&D ~10% of net sales** – Continu
Slide 32: Long history of margin expansion
Long history of margin expansion EBIT • Economics of scale – SEK M volume driven 2 000 improvement 20% 20% 19% • Increasing share of 1 500 17% aftermarket revenues 12% 13% • Leverage on fixed costs 1 000 12% 11% 10% 500 0 EBIT EBIT margin
Slide 33: Operating leverage
Operating leverage Gross margin and SG&A to net sales Gross margin: 50% • Increasing share of 45% aftermarket revenues 40% 35% • Growth with hardware in 30% emerging markets - 25% expanding the installed 20% base 15% 10% SG&A to net sales: 5% 0% • Continue to leverage on 04/05 05/06 06/07 07/08 08/0
Slide 34: Increased investments in R&D of >20% this year
Increased investments in R&D of >20% this year Investments in R&D Focus areas: SEK M % of net sales 1 000 10% 10% • MR Linac • Leadership in cancer care 800 8% with linear accelerators 600 6% • Drive SRS market with Leksell Gamma Knife® 400 4% • Software – capture full potential 200 2% • Brachythera
Slide 35: Full year 2012/13
FULL YEAR 2012/13
Slide 36: All financial targets exceeded
All financial targets exceeded • Order bookings +14%* • Net sales growth +16%* • EBIT growth +17%** • Cash conversion 76% *Based on constant exchange rates ** Excluding non –recurring items
Slide 37: North and South America
Regional overview North and South America • Order bookings up 9%* in FY • North America – Elekta’s order and sales growth was strong in Q4 – Uncertainty on market related to reimbursement and health care reform • Strong momentum in Canada • South America – tender for 80 linear accelerators ongoing i
Slide 38: Europe, Middle East and Africa
Regional overview Europe, Middle East and Africa • Order bookings increased by 29%* in Q4 and grew with 10%* for the fiscal year • Good order development in all major European markets • Improvements in the Middle East during Q4 • Contribution margin: 36% (35) May – Apr May – Apr SEK M Change 2012/13
Slide 39: Asia Pacific
Regional overview Asia Pacific • Order bookings up 23%* in FY • Strong growth in China and India where Elekta is the market leader • Good contribution from “new” emerging Asian markets • Business in Japan continue to grow – positive trend for Toshiba collaboration • Contribution margin: 32% (32) May
Slide 40: Contribution margin development
Contribution margin development SEK M 4 000 37% 37% 35% 36% 3 500 35% 34% 35% 35% 35% 3 000 32% 32% 33% AsiaPacific 2 500 32% EMEA 28% Americas 2 000 27% Americas2 1 500 EMEA2 1 000 AsiaPacific2 500 0 08/09 09/10 10/11 11/12 12/13
Slide 41: Elekta's linac installed base growth: CAGR 9%
Elekta’s linac installed base growth: CAGR 9% No. Installed base CAGR 9% 09/10 10/11 11/12 12/13 Established Markets Emerging Markets • Emerging markets +16% (CAGR) • Established markets +5%
Slide 42: Elekta is taking share from current Siemens installed base
Elekta is taking share from current Siemens installed base Siemens installed base North America: • On track with conversion ~350 linear accelerators of Siemens installed base • Global strategy and Europe AFLAME: dedicated team in place ~ 550 linear accelerators • Comprehensive program Asia Pacific:
Slide 43: Service and software expansion
Service and software expansion • Upgrades – Agility, Flexitron etc. • Updated and expanded service offering – remote services • Drive higher share of software on emerging markets • Professional services Today • Emerging markets 43%
Slide 44: Strong cash generation in 2012/13
Strong cash generation in 2012/13 Cash conversion, % Net working capital/ net sales, % 16% 91% 86% 14% Average: 76% 12% 10% 59% 57% 8% 47% 6% 4% 2% 0% Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 07/08 08/09 09/10 10/11 11/12 12/13 11 11 11 12 12 12 12 13 13 13 13 • Average 6 year cash conversion: • Net working
Slide 45: Negative currency effects
Negative currency effects • Continued volatility on currency markets. End of April changes (Y/Y) SEK M FX exposure 4 000 – USD: -2% - GBP: -7% Operating expenses – JPY: -20% - EUR: -4% Revenues 3 000 • Negative currency effect 2012/13: 2 000 – Net sales: -2% 1 000 – EBIT: SEK 90 M 0 • Estimated curr
Slide 46: Strong balance sheet
Strong balance sheet 12/13 11/12 Liquid assets (SEK M) 2,567 1,895 Net debt (SEK M) 1,985 2,635 Equity (total, SEK M) 5,560 5,010 ROE 27% 29% ROCE 21% 28% Net debt/equity 0.36 0.53 Net debt / EBITDA* 0.82 1.24 * Excluding non –recurring items 45
Slide 47: Long-term financial objectives
Long-term financial objectives Sales growth: >10% Operating result growth to exceed sales growth in SEK ROCE: >20% Net debt / equity: <0.5
Slide 48: Extra dividends proposed
Extra dividends proposed MSEK • Ordinary dividend of 800 SEK 1.50 (1.25) per share CAGR • 3 year program with 600 35% extraordinary dividend of SEK 0.50 per share and 400 year 200 0 * 05/06 06/07 07/08 08/09 09/10 10/11 11/12 12/13 Dividend Extra dividend / repurchase
Slide 49: Outlook fiscal year 2013/14
Outlook fiscal year 2013/14 Human Care Makes the Future Possible C) ELEKTA
Slide 50: 2013/14 - another strong year expected
2013/14 - another strong year expected • Capture all opportunities in emerging markets • Strengthen positions in established markets • R&D investments increase by >20% • Continued leverage on SG&A
Slide 51: Outlook based on EBITA
Outlook based on EBITA • Increased visibility with EBITDA and EBITA specified every quarter • Closer link to cash flow Amortization 2011/12 2012/13 Change (%) R&D 95 107 13% Acquisitions 110 132 20% TOTAL 205 239 17%
Slide 52: Outlook for fiscal year 2013/14
Outlook for fiscal year 2013/14 • For the fiscal year 2013/14, net sales is expected to grow by more than 10%* • EBITA is expected to grow with approximately 10%* • Currency is estimated to have a negative impact of about 3 percentage points on EBITA growth * In local currencies
Slide 53: Region North America
Region North America Jay Hoey Executive Vice President
Slide 54: Good growth in North America
Good growth in North America • 7% of world’s population Order growth • 30% of the world’s linear accelerators CAGR • Most advanced radiotherapy market 11% in the world • Elekta has >60% market share in software (OIS) and brachytherapy. ~25% in new sales of linacs • Demand is driven from aging popula
Slide 55: Well positioned for further growth
Well positioned for further growth Linacs • Versa HD™ roll-out • Siemens opportunity Installed base • Enhance service excellence • Provide advanced solutions – Streamlined workflow = higher efficiency – Advanced treatments = higher effectiveness Software leadership • New software applications for ex
Slide 56: Elekta North America is gaining share
Elekta North America is gaining share Market share - installed base Market share – new orders (FY12/13) (FY12/13) Accuray Elekta Accuray 3% Siemens 5% 13% 9% Elekta 25% Varian 73% Varian 72% Sources: IMV, MD Buyline, Internal Win / Loss reports, Management analysis
Slide 57: USA - world's largest RT market
USA – world’s largest RT market United States • Population: 314 M, cancer incidence: 1.5 M (~0.47%) • ~63% receive radiation therapy Radiation therapy - mainly a replacement market • ~ 80% of linacs are replacement machines Multiple factors drive demand • Higher cancer incidence with aging populatio
Slide 58: US medical device tax and reimbursement
US medical device tax and reimbursement Medical device tax • 2.3% on the majority of hardware and software sales. • Impacting gross profit Reimbursement • CMS proposal in summer • Final decision in autumn
Slide 59: The Canadian market is expanding
The Canadian market is expanding • ~ 32% receive radiation therapy, government goal is 48% • Population: 36 M, cancer incidence: 0.2 M (~0.51%) • Excellent growth in Ontario • Linear accelerators replaced as part of government health agency replacement cycles (10-12 years for linacs) • Interesting m
Slide 60: Increased medical initiatives in Mexico
Increased medical initiatives in Mexico • Installed base: ~ 80 linacs installed ~ 25 cobalt units • ~70% government and ~30% private • Government initiatives with funding approved for expanding in radiation medicine • Private sector will expand radiotherapy and OIS segments (updating installed base)
Slide 61: Elekta is growing
Elekta is growing • Technology leadership – Versa HD™ • Highest standard in service and aftermarket support • Focus on comprehensive solutions and partner with customer • Leverage on strong footholds within software (OIS) and brachytherapy
Slide 62: Top customer satisfaction in the US
Top customer satisfaction in the US
Slide 63: Human Care Makes the Future Possible
Human Care Makes the Future Possible
Slide 64: Region Europe & AFLAME
Region Europe & AFLAME Ian Alexander Executive Vice President Europe & AFLAME
Slide 65: Elekta is the market leader in the region
Elekta is the market leader in the region Order development Emerging CAGR market share 15% ~40% 06/07 07/08 08/09 09/10 10/11 11/12 12/13 Installed base: • ~1,200 linacs • ~60 Leksell Gamma Knife units
Slide 66: Strong growth in revenues and contribution in 2012/13
Strong growth in revenues and contribution in 2012/13 • Net sales up 11% or 15% in local currencies – strong growth: – Germany – UK – Nordics, Italy and France • Contribution margin up 17 % to 36% (35) – Growing installed base – Operational leverage May – Apr May – Apr SEK M Change 2012/13 2011/12 N
Slide 67: Elekta is growing more than the installed base
Elekta is growing more than the installed base Share of order intake Share of installed base (FY12/13) (FY12/13) Accuray 3% Other 6% Siemens 1% 18% 32% Elekta Siemens Varian 42% 54% Elekta 44% Varian
Slide 68: Leader in both established and emerging markets
Leader in both established and emerging markets Established markets Emerging markets Share of order intake Share of order intake (FY12/13) (FY12/13) Accuray 3% Accuray 3% Siemens 4% Varian 45% 48% Elekta Varian 39% 58% Elekta Varian
Slide 69: Market characteristics
Market characteristics Emerging Established • Green field expansion • Installed base mgmt • Need for training/ • After sales and services education • Replacements • Financing • Technology focused • Reference centers • Success stories • Site visits • Know-how & • Credibility experience
Slide 70: Market dynamics by key markets
Market dynamics by key markets Eastern Europe Established Europe • Russia important market and • Mainly replacement or key strength expansion of existing sites • Developing distribution network • Early adopters of new to address opportunities in technology emerging markets Middle East • Strong end o
Slide 71: Established markets - strengthen positions
Established markets – strengthen positions • Good growth in central- and northern Europe • Upgrade of maturing installed base in many markets • Opportunities created by exit of Siemens. Elekta capture rate >50% • Drive usage of radiation therapy on market; In UK only 38% of cancer patients receive R
Slide 72: Versa HD - great customer response
Versa HD™ – great customer response ESTRO 2013 - Geneva • Sold to 10 countries in the region • Elekta has a strong position in University Hospitals/Clinics • Good opportunity with Versa HD™ • Well attended Versa HD Launch meeting in Istanbul
Slide 73: Emerging markets - No. 1 market position
Emerging markets - No. 1 market position • Affordability, Training and Education • Russia: 10-15 clinics are equipped every year; current NOP entering final cycle • Additionally Regional authorities funding 2-4 new RT centers per year • Elekta in planning phase for local manufacturing and E&T Center
Slide 74: Strong market development in Latin America
Strong market development in Latin America Brazil • Brazil: Ministry of Health Colombia major purchasing program • 45 million (80 new linacs) delayed, • Growth in public and private but expecting completion sector • Knock-on impact into other • 42 linacs (6 Elekta, public and private market 7 Siemen
Slide 75: Good growth on African continent
Good growth on African continent • Yearly incidence of cancer about 713,000 • Africa needs more than 700 additional machines • Barriers to access in Africa: lack of trained oncologists, physicists and technicians • The regions of north Africa and southern Africa together contained 90 percent of the
Slide 76: Region Asia Pacific
Region Asia Pacific Gilbert Wai Executive Vice President Asia Pacific
Slide 77: Market leader in Asia Pacific
Market leader in Asia Pacific New order intake 12/13 Success factors Other 8% • Early establishment e.g. in China since 1982 Accuray 4% • 800 employees • Build up strong local organization with local talent – China, India, Australia 50% Elekta • Strategic investment in Varian 38% – R&D, manufacturin
Slide 78: Strong profitable growth
Strong profitable growth • Strong growth in high growth markets Revenues such as China and India CAGR • Elekta is gaining market share 28% • Growth within service and software • Good volumes of Siemens conversions 07/08 08/09 09/10 10/11 11/12 12/13 77
Slide 79: Trends and future prospects in Asia
► Trends and future prospects in Asia Chinese healthcare market Business update
Slide 80: Asia - a continent of opportunities
Asia – a continent of opportunities • 59% of the world’s population • 30% of the world’s land area • 32% of the world’s GDP (2011) • Less than 30% of the world linacs • Less than 1 linac per million people in many markets
Slide 81: Solid underlying growth drivers
Solid underlying growth drivers Asia – distribution of population 2010 2050 Age (years) Age (years) Male Female Male Female • Aging population – driving cancer incidence • Improving diagnostics • Awareness about cancer – training and education • Radiation therapy - significantly more cost efficient
Slide 82: Rapid urbanization of Asia
Rapid urbanization of Asia Million 6 000 Total population Urban population 5 000 4 000 64.5% 3 000 58.8% 47.2% 2 000 42.2% 42.2% 36.8% 1 000 31.5% 0 1990 2000 2010 2020 2030 2040 2050 Source: World Urbanization Prospects, UN Population Division 2009 Anil K. Gupta, The Changing Dynamic, October 2012.
Slide 83: APAC healthcare expenditure will increase significantly by 2020
APAC healthcare expenditure will increase significantly by 2020 India China Japan $331 billion $1,446 billion $563 billion APAC CAGR 14.5% CAGR 15.5% CAGR 3.0% $ 2,927 billion 151% increase 2010-2020 CAGR 9.2% G7 $ 6,147 billion 50% increase 2010-2020 CAGR 4.0% BRIC $ 1,958 billion 212% increase 201
Slide 84: Number of hospital beds by 2015 in Asia Pacific
Number of hospital beds by 2015 in Asia Pacific China – 2015 Total beds: 3,248,480 Public: 94% Private: 6% India – 2015 Total beds: 644,768 Public: 58% Private: 42% Indonesia – 2015 Total beds: 107,796 Public: 64% Private: 36% Source: Frost and Sullivan and company data
Slide 85: Mortality rate disproportionate due to unmet need and lack of professionals
Mortality rate disproportionate due to unmet need and lack of professionals Cancer incidence and mortality by country, 2008 70% Mortality rate Country Incidence Mortality China 2,817,200 1,958,300 39% Mortality rate USA 1,437,200 565,600 India 948,900 633,500 Japan 615,500 342,200 Australia 106,900
Slide 86: Adapt to local needs - cancer incidence
Adapt to local needs - cancer incidence Number of new cancer cases per year Male Female Lung Breast Stomach Cervix uteri Liver Lung Colorectum Stomach Oesophagus Colorectum Prostate Liver Bladder Corpus uteri Leukaemia Oesophagus Lip, oral cavity Ovary Non-Hodgkin… Leukaemia Source: Globocan 2008
Slide 87: Accessibility - education and training overview
Accessibility- education and training overview Elekta training facilities Elekta training facilities Sydney, Australia Shanghai, China Chennai, India (Nucletron) EBMEI, Beijing, China Zhouzhou Hospital, China TMSC Nasu facility, Japan (Toshiba) Customer training facilities 17 leading institutes
Slide 88: Chinese healthcare market
Trends and future prospects in Asia ► Chinese healthcare market Business update
Slide 89: Healthcare in China
Healthcare in China - a great opportunity for the future! • Large unmet need • Lack of treatment capacity and competence • Need for cost effective solutions Great progress is being made and success of current health care reform – a key for the future!
Slide 90: Hospital structure in China
Hospital structure in China Hospitals (~1,300) Class III >500 beds Class II hospitals (~6,000) >100 beds Class I and other small hospitals (~13,000) <100 beds 89
Slide 91: More than 95% is covered by an insurance
More than 95% is covered by an insurance Covered population (million) Eligibility 2006 2010 • Mandatory basic health insurance for urban Urban Employee employees of state-owned or private Basic Medical enterprises 160 240 Insurance • Funded by employers and employees (UEBMI) • Current annual premium
Slide 92: Need of training and education in China
Need of training and education in China RT Physician Physcist Nurse RTT Engineer Source: Prof. Li, Nov. 2011
Slide 93: Education and collaboration support to key universities
Education and collaboration support to key universities The selected Universities: Tsinghua University Wuhan University Tianjing University
Slide 94: Business update
Trends and future prospects in Asia Chinese healthcare market ► Business update
Slide 95: China - second largest market for Elekta
China – second largest market for Elekta • Elekta has a No. 1 position • Achieved 42% growth in order bookings • 500 employees Shinva/other 15% 48% Elekta Varian 37% New order intake 12/13
Slide 96: Elekta in China - great success
Elekta in China - great success Net sales 1 200 1 000 CAGR 800 29% 600 400 200 0 08/09 09/10 10/11 11/12 12/13
Slide 97: Elekta is the market leader in India
Elekta is the market leader in India • Elekta is no.1 and achieved ~60% growth in order bookings 2012/13 • Growth in Indian market is expected to be significant over the next years Other • Standard of treatment continues 8% to improve across region Varian 37% 55% Elekta New order intake 12/13
Slide 98: Japan - continued high growth
Japan – continued high growth Brainlab • Elekta achieved 14% growth Accuray 10% in order bookings 2012/13 9% 37% Elekta • Elekta dominates in neuroscience and treatment planning Varian 44% • Distribution agreement with Toshiba successfully replacing New order intake 12/13 Siemens installed base
Slide 99: Priorities for Asia Pacific
Priorities for Asia Pacific • Develop infrastructure to support the entire region including training and education • Adapted range of solutions to suit all market needs • Expand software and service business • Capture full Siemens opportunity
Slide 100: Human Care Makes the Future Possible
Human Care Makes the Future Possible
Slide 101: Summary
Summary Human Care Makes the Future Possible
Slide 102: Strategic agenda 2015/16 - focused on growth
Strategic agenda 2015/16 - focused on growth Ambition to grow net sales by 40%* from 2012/13 to 2015/16 1. Higher share of cancer care 2. Emerging markets – Availability – Training and education 3. Technology leadership – Image guided radiation therapy – MR Linac – Stereotactic radiation therapy and
Slide 103: Elekta CMD 2013
ELEKTA CMD 2013 C) ELEKTA